Tonix Pharmaceuticals Holding Corp

NASDAQ:TNXP   3:58:33 PM EDT
1.05
-0.02 (-1.42%)
Products, Regulatory

Tonix Pharmaceuticals Reports Topline Results From Phase 3 Recovery Study Of TNX-102 Sl In PTSD And Outlines Future Development Plans

Published: 12/21/2020 12:23 GMT
Tonix Pharmaceuticals Holding Corp (TNXP) - Tonix Pharmaceuticals Reports Topline Results From Phase 3 Recovery Study of Tnx-102 Sl in Ptsd and Outlines Future Development Plans.
Tonix Pharmaceuticals Holding Corp - Primary Endpoint for Full Cohort of Enrolled Participants Did Not Achieve Statistical Significance.
Tonix Pharmaceuticals Holding Corp - Encouraging Activity of Tnx-102 Sl Observed in Secondary Endpoints.
Tonix Pharmaceuticals Holding Corp - Tnx-102 Sl Generally Well Tolerated; No New Safety Signals Observed: No Change in Weight Or Blood Pressure.
Tonix Pharmaceuticals Holding Corp - Planning Development of Tnx-102 Sl for Treatment of Ptsd Sleep Disturbance Indication, Pending FDA Discussion.